-
Signature
-
/s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC
-
Issuer symbol
-
TNGX
-
Transactions as of
-
11 Aug 2023
-
Net transactions value
-
+$14,499,998
-
Form type
-
4/A - Amendment
-
Filing time
-
11 Oct 2023, 19:22:22 UTC
-
Date Of Original Report
-
15 Aug 2023
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
TNGX |
Common Stock |
Award |
$2,446,250 |
+475,000 |
+177% |
$5.15 |
743,542 |
11 Aug 2023 |
See footnote |
F1 |
| holding |
TNGX |
Common Stock |
|
|
|
|
|
7,123,642 |
11 Aug 2023 |
Direct |
F2 |
| holding |
TNGX |
Common Stock |
|
|
|
|
|
5,000 |
11 Aug 2023 |
See footnote |
F3 |
| holding |
TNGX |
Common Stock |
|
|
|
|
|
26,961 |
11 Aug 2023 |
See footnote |
F4 |
| holding |
TNGX |
Common Stock |
|
|
|
|
|
6,988,450 |
11 Aug 2023 |
See footnote |
F5 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
TNGX |
Prefunded Warrant |
Award |
$12,053,748 |
+2,340,579 |
|
$5.15 |
2,340,579 |
11 Aug 2023 |
Common Stock |
2,340,579 |
|
Direct |
F2, F6 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
This amended Form 4, which amends and restates in its entirety the original Form 4 filed on August 15, 2023, corrects the transaction codes in the original filing. These acquisitions were made in transactions with the Company under Rule 16b-3, as opposed to open market purchases. The reporting persons may be deemed members of a group that beneficially owns more than 10% of the outstanding shares of common stock, $0.001 par value per share, of Tango Therapeutics, Inc. (the "Issuer"). At the time of the transactions reported herein, Mr. Davis was a director of the Issuer and the other reporting persons were subject to Section 16 as directors of the Issuer on the basis of their relationships to Mr. Davis.